Wow! mystery signal from space finally explained


https://phys.org/news/2017-06-wow-mystery-space.html

Mounjaro, Newly Approved, Might Just Be the Best Type 2 Diabetes Drug Ever


A brand new drug has been approved for patients with type 2 diabetes, and it’s now available. It may prove to be the most effective type 2 diabetes drug ever developed.

The drug is tirzepatide (Mounjaro), and it is the innovation of the pharmaceutical giant Eli Lilly and Company.

In Trials, Mounjaro’s Benefits Are Unprecedented

Mounjaro is a highly effective glucose-lowering injection that also leads to impressive and apparently effortless weight loss.

As earlier reported by our friends at diaTribe, tirzepatide (Mounjaro) has been tested in multiple large clinical trials, all of which showed that the medication leads to extraordinary blood sugar improvements for patients with type 2 diabetes.

I’ll review just one such trial in detail: the SURPASS-1 Trial, which tested the new pharmaceutical for 40 weeks in nearly 500 patients with type 2 diabetes.

  • A1C. The patients, who began the trial with an average A1C of 7.9%, enjoyed A1C reductions of 1.9 to 2.1%. At the end of the trial, a strong majority of patients (81-86%) saw their A1C fall to below 6.5%, outside of the diabetic range. About 50% who used the highest dosage saw their A1C fall to less than 5.7%, completely out of the pre-diabetes range.
  • Fasting Blood Sugar. The average fasting blood sugar of patients declined by 44-49 mg/dL!
  • Weight loss. Participants lost an average of 15 pounds (at the 5mg dosage) to 21 pounds (at the 15mg dosage).
  • Cholesterol. Triglycerides and LDL cholesterol both went significantly down; HDL (“good cholesterol”) went significantly up.

Other trials had similar results in slightly different populations: astounding blood sugar improvements and weight loss, and other health benefits to boot.

These numbers easily surpass the results observed in other diabetes medications already on the market.

Mounjaro even outperformed daily injections of insulin, widely considered the most powerful glucose-lowering treatment, in two trials. Not only did Mounjaro users enjoy superior blood sugar improvements than insulin users, they also had a significantly reduced risk of hypoglycemia. (Mounjaro also works well when used with insulin.)

Mounjaro and Weight Loss

And then there’s the matter of the miraculous weight loss. Every one of the trials mentioned above showed that Mounjaro patients lost a massive amount of body weight.

If anything, doctors (and investors) are even more excited about tirzepatide’s potential as a weight-loss drug than as a diabetes drug. We covered this extensively in a recent story: These Two Diabetes Drugs Could Completely Change Weight Loss and Obesity Treatment.

At its highest dosage, tirzepatide helped overweight patients lose 22.5% of their body weight in 72 weeks, a completely jaw-dropping result on par with the massive benefits from bariatric surgery. Even at its lowest dosage, 5mg, patients lost an average of 35lb.

To put it simply, this appears to be the most promising weight loss drug ever invented. Although it has not yet been approved as a weight-loss drug, patients that use it for diabetes will be the first to enjoy these benefits.

Assuming it is eventually approved as a weight-loss medication, tirzepatide may be marketed separately for weight loss under a different name than “Mounjaro.”

How Does Mounjaro Work?

Mounjaro is related to the class of drugs known as GLP-1 receptor agonists. These medicines work for patients with type 2 diabetes by mimicking the effects of the hormone glucagon-like peptide 1 (GLP-1), which is usually released by the intestine during meals. GLP-1 does a variety of things: It tells the liver to release less glucose, it slows digestion, and it provokes the feeling of fullness or satiety. Put it all together, and when patients with diabetes take the drug it reduces blood glucose levels while also helping them eat less.

There are several GLP-1 receptor agonists already available for patients with diabetes. In the United States, they’re sold under the following brand names:

  • exenatide (Byetta, Bydureon)
  • liraglutide (Victoza)
  • lixisenatide (Adylixin)
  • dulaglitide (Trulicity)
  • semaglutide (Ozempic, Rybelsus)

GLP-1 receptor agonists work for patients with type 2 diabetes by mimicking the effects of the hormone GLP-1, which is released by the intestine during meals. GLP-1 does a variety of things: It tells the liver to release less glucose, it slows digestion, and it provokes the feeling of fullness or satiety. Put it all together, and when patients with diabetes take the drug it reduces blood glucose levels while also helping them eat less.

Mounjaro has all of those positive effects, but it additionally mimics another hormone, glucose-dependent insulinotropic polypeptide (GIP). The combination appears to be even more effective.

Cost and Availability

Mounjaro, unsurprisingly, is quite pricey. As of this update, filed in November 2022, the sticker price is about $1,000 per month. The cost is likely to remain high for the foreseeable future, although we can hope that insurers become increasingly eager to cover that cost, given the impressive benefits.

There’s no word yet on availability in other countries. Competitor Wegovy has been so popular in the United States that its maker has temporarily hit the brakes on advertising its new miracle drug.

A Few Details

Mounjaro is not intended to replace the most important therapies for type 2 diabetes: diet and exercise.

Mounjaro is not a pill; it is self-administered by injection once a week. It will come in the form of an auto-injector pen, similar to an insulin pen, that does not require patients to draw up the medicine themselves. Lilly will market six different dosages, from 2.5mg up to 15mg. New patients are recommended to begin with a starter dose of 2.5mg and gradually work up to larger amounts over a period of months.

Some side effects (particularly gastrointestinal distress) and contraindications have been announced. Because Mounjaro has been found to cause tumors in the thyroids of rats, regulators are recommending that people with a family history of thyroid cancer or multiple endocrine neoplasia syndrome type 2 do not use it. It may be inappropriate for patients with pancreatitis.

Mounjaro is not intended for patients with type 1 diabetes, but there is some hope that it could help the condition. GLP-1 receptor agonists appear to be effective for patients with T1D (when used in addition to insulin), and some doctors prescribe them off-label. It may be years before Lilly receives full approval for that use, if indeed it ever happens.

Mounjaro has not yet been thoroughly evaluated in teenagers or children.

Why Metformin Is No Longer the First Drug Option for Type 2 Diabetes


Metformin is the world’s most-prescribed diabetes drug. For a generation, most Americans with newly diagnosed type 2 diabetes have been prescribed metformin as their first medication.

But now metformin’s reign as the universally acknowledged “first-line” treatment for type 2 diabetes has come to an end. Updated guidance from the American Diabetes Association (ADA), released on December 12, 2022, has substantially minimized the importance of the popular drug. The ADA’s committee of experts removed metformin from key recommendations and now ranks the drug as inferior to other options for blood sugar control, weight loss, and long-term heart and kidney protection.

As a result, the ADA has essentially abandoned the idea of a universal “first-line therapy.” The organization removed multiple significant references to the concept and replaced them with language encouraging clinicians to consider many different medicines for new patients.

“Current treatments are absolutely not one-size-fits-all anymore,” said Robert Gabbay, MD, PhD, chief science and medical officer for the ADA. He told Diabetes Daily that the new recommendations are “about tailoring the therapy based on the patient’s needs.”

The likely result? More patients will be prescribed newer drugs — SGLT-2 inhibitors and GLP-1 and GIP/GLP-1 receptor agonists — that are both more effective and far more expensive.

A New Progression

The standard treatment progression of previous years — prescribe metformin, monitor the results, and only later prescribe additional medications — has been overturned for an approach that is more complex and potentially more aggressive. Now, doctors are encouraged to consider all diabetes drugs from the very beginning. Previously, the immediate use of drugs more powerful than metformin had been limited to new patients with “special circumstances.”

“It is more about elevating the importance of cardiorenal protective drugs, and not necessarily waiting to start metformin and then move on to the cardiorenal protective medications,” says Dr. Gabbay.

The change was revealed in the newest version of the ADA’s Standards of Care in Diabetes, the guide that establishes diabetes treatment standards for healthcare providers in the United States. This year’s update deleted prominent references to the idea of a “first-line” or “initial” therapy, and has removed metformin from its perch at the top of its signature flowchart.

The U.S. Food and Drug Administration (FDA) appears to be moving in a similar direction. On January 13, the organization announced a label update for Rybelsus, an oral GLP-1 receptor agonist, allowing it to be used as a first-line treatment for type 2 diabetes. Previously, the drug had not been officially indicated for initial therapy. 

New Drugs Give Doctors New Treatment Targets

The new ADA recommendation can be seen as a major endorsement for the stars of the newest generation of diabetes drugs: SGLT-2 inhibitors and GLP-1 and GIP/GLP-1 receptor agonists. These options combat hyperglycemia effectively but add other important benefits that metformin cannot claim: enhanced weight loss and more robust protection against cardiovascular and kidney disease.

The latest Standards of Care puts those new treatment targets at the forefront by recommending that patients with additional metabolic health conditions, such as obesity or a high risk of heart disease, should be offered diabetes drugs that address those conditions.

Jeffrey Mechanick, MD, an endocrinologist at New York’s Mount Sinai Hospital, is a supporter of the change. Dr. Mechanick was not involved with the new ADA document but has helped author guidelines for the American Academy of Clinical Endocrinology. He told me that “we needed a paradigm shift.”

Mechanick explained that diabetes experts have moved away from their previous focus on hyperglycemia toward more “comprehensive” approaches. The shift was largely inspired by the results of major clinical trials, beginning with 2008’s ACCORD trial, which unexpectedly showed that aggressively lowering glucose levels with medications such as insulin and sulfonylureas could introduce harm. Next, a series of renal and cardiovascular outcome trials found that the new generation of diabetes drugs protected the kidney, heart, and blood vessels, reducing complications and even saving lives.

“The ordinary physician, when confronted with a patient, shouldn’t just keep adding medicine and adding medicine in order to treat a particular numerical target like A1C or fasting blood sugar,” says Mechanick.

“It’s good that it’s in the guideline. It helps healthcare professionals know that, all things being equal, [newer drugs] would be a better way to manage a patient.”

Reranking Metformin

The new Standards of Care includes a flowchart that offers the best way to visualize who ought to consider more powerful drugs than metformin:

  • For patients who need to lose weight — reportedly 80 to 90 percent of people with type 2 diabetes — the ADA ranks drugs by efficacy, with semaglutide (a GLP-1 receptor agonist) and tirzepatide (a GIP/GLP-1 receptor agonist) conferring the most weight loss. These two drugs induce levels of weight loss that are unprecedented in obesity medicine.
  • The ADA now recommends patients with a high risk of atherosclerotic cardiovascular disease, and those who have already developed the condition, take either a SGLT2 inhibitor or a GLP-1 receptor agonist.
  • The standards also suggest patients with heart failure or chronic kidney disease should take an SGLT2 inhibitor.

A very substantial majority of people with type 2 diabetes fall into one or more of the above categories. While metformin is still a potent therapy — it is scored as “high” efficacy for lowering glucose — it is now only one of several preferred options for treating hyperglycemia.

Mechanick told Diabetes Daily that clinicians “should be thinking of the GLP-1s and SGLT2s much, much earlier. They should think of prescribing these drugs first … if the insurance company will pay for it.”

Money Matters

As of this writing, empagliflozin (Jardiance), an SGLT2 inhibitor, costs nearly $600 per month off the shelf. Semaglutide (Ozempic), a GLP-1 receptor agonist, is over $900. Tirzepatide (Mounjaro), the GIP/GLP-1 receptor agonist that Diabetes Daily called “the best type 2 diabetes drug ever,” costs about $1,000. It will be many years before generics can be developed and approved.

Few members of the diabetes community can afford to pay such prices out of their own pockets, and insurers may be reluctant to cover such pricey medications for new patients without special circumstances.

Mechanick explained that “there was incredible reluctance to elevate GLP-1s and SGLT2s, because they’re really not accessible to everybody.” Endorsing the earlier use of these newer drugs “is consistent with our modern understanding of diabetes and chronic disease prevention, but there are practical issues in mind. It’s just not pragmatic because patients can’t afford it.”

Gabbay insisted that the ADA is “very concerned about access to treatment and the unfortunate health disparities that exist in the diabetes community.” He highlighted the ADA’s Health Equity Now advocacy program as one way that the organization is combating diabetes inequities.

“Metformin still plays an important role for many patients,” says Gabbay, and even if metformin doesn’t offer the comprehensive benefits of the newest drugs, it remains both safe and affordable. Diabetes treatment will not change overnight. Mechanick noted that “just because something’s in a guideline, it doesn’t mandate that it’s done.” 

Eventually, insurers may become convinced that SGLT2 inhibitors and GLP-1 and GIP/GLP-1 receptor agonists pay for themselves by reducing the likelihood of complications such as heart and kidney disease. In the meantime, however, it’s easy to envision a near future in which metformin becomes the de facto first-line therapy of the less advantaged. A recent study in The Lancet found that there are already stark racial/ethnic and socioeconomic divides in the use of newer diabetes medications, particularly GLP-1 receptor agonists. It’s unclear if the new ADA recommendations will help bridge those gaps or widen them.

Diabetic Neuropathy Symptoms in Mice Eased Using Serine Amino Acid Supplement


Studies in mice by a Salk Institute research team have shown how altered amino acid metabolism can represent a contributing factor to diabetes-associated peripheral neuropathy. Their experiments found that diabetic (db/db) mice with low levels of two related amino acids, serine and glycine, were at higher risk for peripheral neuropathy. The symptoms of neuropathy in these mice could also be alleviated by supplementing the animals’ diets with serine. The study adds to growing evidence that some “non-essential” amino acids (NEAA) play important roles in the nervous system. The results may also point to a new way to identify people at high risk for peripheral neuropathy, as well as a potential treatment option.

“We were surprised that dialing up and down a non-essential amino acid had such a profound effect on metabolism and diabetic complications,” said Christian Metallo, PhD, a professor in Salk’s Molecular and Cell Biology Laboratory. “It just goes to show that what we think of as dogma can change under different circumstances, such as in disease conditions.” However, the researchers do also say that it would be premature to advise people with diabetes to take serine supplements to prevent neuropathy. “You would likely need to take a lot to make a difference, and not everyone needs extra serine,” Metallo added “We need more time to understand serine physiology in humans and explore potential downsides to supplementation.”

Metallo led the study with Michal Handzlik, PhD, a postdoctoral researcher in his lab, who is first author of the team’s published paper Nature, which is titled “Insulin-regulated serine and lipid metabolism drive peripheral neuropathy.” In their report they concluded, “These findings identify systemic serine deficiency and dyslipidaemia as novel risk factors for peripheral neuropathy that may be exploited therapeutically.”

Diabetes represents a spectrum of disease in which metabolic dysfunction damages multiple organ systems including liver, kidneys and peripheral nerves, the authors explained. “Although the onset and progression of these co-morbidities are linked with insulin resistance, hyperglycaemia and dyslipidaemia, aberrant non-essential amino acid (NEAA) metabolism also contributes to the pathogenesis of diabetes.” Serine and glycine are closely related NEAAs, levels of which have been found to be reduced in patients with metabolic syndrome, but the mechanistic drivers and downstream consequences of this aren’t understood, the team continued. “Low systemic serine and glycine are also emerging as a hallmark of macular and peripheral nerve disorders, correlating with impaired visual acuity and peripheral neuropathy.”

Approximately half of people with type 1 or type 2 diabetes experience peripheral neuropathy—weakness, numbness, and pain, primarily in the hands and feet. The condition occurs when high levels of sugar circulating in the blood damage peripheral nerves.

Amino acids are the building blocks that make up proteins and specialized fat molecules called sphingolipids, which are abundant in the nervous system. Low levels of the amino acid serine force the body to incorporate a different amino acid in sphingolipids, which changes their structure. These atypical sphingolipids then accumulate, which may contribute to peripheral nerve damage.

While Metallo and his team observed this accumulation in their diabetic mouse models, the same amino acid switch and sphingolipid changes also occur in a rare human genetic disease marked by peripheral sensory neuropathy, indicating that the phenomenon is consistent across many species.

To determine whether long-term, chronic serine deficiency drives peripheral neuropathy, Metallo’s team fed mice either control or serine-free diets in combination with either low-fat or high-fat diets for up to 12 months. The researchers were surprised to find that low serine, in combination with a high-fat diet, accelerated the onset of peripheral neuropathy in the mice. In contrast, serine supplementation in diabetic mice slowed the progression of peripheral neuropathy, and the mice fared better. “Collectively, these data suggest that supplementation of serine can slow the progression of diabetic peripheral neuropathy,” they wrote.

The researchers also tested the compound myriocin, which inhibits the enzyme that switches out serine for another amino acid as sphingolipids are assembled. They found that myriocin treatment reduced peripheral neuropathy symptoms in mice fed a high-fat, serine-free diet. “Normalization of serine by dietary supplementation and mitigation of dyslipidaemia with myriocin both alleviate neuropathy in diabetic mice, linking serine-associated peripheral neuropathy to sphingolipid metabolism,” the researchers stated. These findings underscore the importance of amino acid metabolism and sphingolipid production in the maintenance of a healthy peripheral nervous system. “Our results highlight physiologically relevant molecular links between serine and glycine homeostasis, sphingolipid metabolism, and diabetic co-morbidities,” they further stated. “Normalizing circulating serine levels via dietary  supplementation delays the onset and progression of sensory neuropathy in db/db mice.”

Serine deficiency has been associated with various neurodegenerative disorders. Metallo and collaborators previously found a link between altered serine and sphingolipid metabolism in patients with macular telangiectasia type 2, a condition that causes vision loss. In mice, reduced serine led to increased levels of atypical retinal sphingolipids and reduced vision. Serine is currently being tested in clinical trials for its safety and efficacy in treating macular telangiectasia and Alzheimer’s disease. “… supplementation of serine and B vitamins improves peripheral neuropathy in some preclinical models and are the focus of clinical trials for various neurodegenerative disorders,” the researchers added.

Peripheral neuropathy is typically managed with dietary changes—to reduce blood sugar levels—as well as using pain relievers, physical therapy, and mobility aids, such as canes and wheelchairs. Foods naturally rich in serine include soybeans, nuts, eggs, chickpeas, lentils, meat, and fish, and serine supplements are inexpensive and available over the counter. The researchers are not, however, advocating that diabetes patients should take serine supplements to prevent neuropathy.

Metallo and Handzlik are developing a serine tolerance test (STT), similar to a glucose tolerance test that is used to diagnose diabetes. “We want to identify those at highest risk for peripheral neuropathy so we can treat only those who might benefit most,” Handzlik said. The authors further suggested, “Here we demonstrate that aberrant serine homeostasis drives serine and glycine deficiencies in diabetic mice, which can be diagnosed with a serine tolerance test that quantifies serine uptake and disposal … A STT, analogous to an oral glucose tolerance test (OGTT), could identify patients that exhibit elevated, postprandial serine disposal and who might be particularly susceptible to sensory neuropathy.”

A 16-Year-Old Girl with Abdominal Pain and Bloody Diarrhea


Presentation of Case

Dr. Erin E. Mauney (Pediatrics): A 16-year-old girl was admitted to this hospital because of abdominal pain and bloody diarrhea.

The patient had been well until 5 weeks before this admission, when diarrhea and intermittent, diffuse, crampy abdominal pain developed. During the subsequent week, the diarrhea occurred more frequently, and the abdominal pain worsened in severity, such that it sometimes awoke the patient from sleep. Four weeks before this admission, the diarrhea began to contain dark-red blood. The patient’s mother took her to the primary care clinic of another hospital.

In the primary care clinic, the weight was 98.7 kg; the physical examination was otherwise normal. The hemoglobin level was 12.5 g per deciliter (reference range, 12.0 to 16.0). Stool cultures for salmonella, shigella, campylobacter, and Escherichia coli O157:H7 were negative, as were antigen tests for giardia, cryptosporidium, and Clostridioides difficile toxin. Empirical treatment with ciprofloxacin was started.

During the next 3 weeks, the patient completed the course of ciprofloxacin as instructed, but the abdominal pain and bloody diarrhea continued. On the day of this admission, diarrhea occurred at least four times. The patient’s parents called the primary care clinic and were instructed to bring her to the emergency department of this hospital.

On evaluation, the patient reported fatigue, malaise, weight loss, decreased appetite, and intermittent nausea and vomiting when she ate food. She also had headache and mild, diffuse joint and muscle pain. She had had no fever or sick contacts.

The patient had obesity, anxiety, and attention deficit–hyperactivity disorder (ADHD). Medications included fluoxetine and dextroamphetamine–amphetamine; there were no known drug allergies. Menarche had occurred when she was 11 years of age, and her last menstrual period had been 2 months earlier. She did not drink alcohol or use illicit drugs, and she did not vape or smoke tobacco. The patient lived in a rural area of New England with her mother, father, and sister, as well as her pet dog, cat, and lizard. She attended a technical high school with an emphasis on agriculture, and she had frequent interactions with marine and farm animals through school. Her family history included colorectal cancer and amyotrophic lateral sclerosis in her maternal grandfather, diverticulosis in her maternal grandmother and mother, psoriasis in her maternal grandmother and uncle, and celiac disease in her paternal cousin. Her father had hyperlipidemia, and her mother had had one miscarriage, which had occurred in the first trimester of pregnancy.

On examination, the temporal temperature was 36.4°C, the heart rate 112 beats per minute, and the blood pressure 94/68 mm Hg. The weight was 89.8 kg, and the body-mass index (the weight in kilograms divided by the square of the height in meters) was 32.7. The patient appeared pale, tired, and uncomfortable because of pain. The mucous membranes were dry. The abdomen was nondistended, and there was mild tenderness in both lower quadrants. There was no ulceration or rash.Table 1. Laboratory Data.

The white-cell count was 10,690 per microliter (reference range in children 12 to 17 years of age, 4500 to 10,700), the platelet count 188,000 per microliter, and the hemoglobin level 9.8 g per deciliter. The blood level of C-reactive protein was 248.0 mg per liter (reference range, 0.0 to 8.0), and the erythrocyte sedimentation rate was 71 mm per hour (reference range, 0 to 20). The blood levels of electrolytes and glucose were normal, as were the results of kidney-function tests. Other laboratory test results are shown in Table 1. Testing for severe acute respiratory syndrome coronavirus 2 was negative. Intravenous fluids, acetaminophen, and ondansetron were administered, and the patient was admitted to this hospital.

On hospital day 2, the hemoglobin level was 8.2 g per deciliter, and one unit of packed red cells was transfused. Esophagogastroduodenoscopy (EGD) and colonoscopy were performed.Figure 1. Images Obtained during Esophagogastroduodenoscopy and Colonoscopy.

Dr. Maureen M. Leonard: On EGD, two cratered esophageal ulcers were located 30 cm from the incisors (Figure 1A). The proximal, middle, and distal portions of the esophagus were normal. Diffuse mild inflammation — characterized by erythema and friability — was found in the cardia, gastric fundus, and gastric antrum (Figure 1B). The duodenum appeared normal. Biopsy specimens were obtained throughout the procedure for histologic evaluation.

When the patient was being positioned on the procedure table for the colonoscopy, a large volume of bright-red blood was noted to be draining from the rectum. Perianal and digital rectal examinations did not reveal a source of bleeding. Emergency radiography of the abdomen did not reveal free air, and the colonoscopy was started. On colonoscopy, the rectum and proximal sigmoid colon appeared normal (Figure 1C). However, as the colonoscope was advanced farther into the sigmoid colon, multiple nonobstructing, large, friable, dark-violet lesions were identified and biopsied (Figure 1D, 1E, and 1F). Because of narrowing and severe friability, the area was not traversed with the endoscope, and the procedure was aborted.

Dr. Mauney: The patient was transferred to the pediatric intensive care unit of this hospital. During the subsequent 2 days, an additional two units of packed red cells were transfused. Treatment with pantoprazole was started.Figure 2. Initial Imaging Studies.

Dr. Sjirk J. Westra: Computed tomography (CT) of the abdomen and chest was performed (Figure 2A through 2D). There was irregular thickening of the large bowel wall and adjacent fat stranding, with sparing of the distal sigmoid colon and rectum. The kidneys had multifocal patchy areas of hypoattenuation.

Dr. Mauney: On hospital day 5, tachycardia and tachypnea developed. The hemoglobin level was 8.8 g per deciliter, and the platelet count was 67,000 per microliter. The prothrombin time was 17.3 seconds (reference range, 11.5 to 14.5), the prothrombin-time international normalized ratio 1.4 (reference range, 0.9 to 1.1), the activated partial-thromboplastin time 50.0 seconds (reference range, 22.0 to 36.0), and the blood d-dimer level greater than 10,000 ng per milliliter (reference range, 0 to 500). Other laboratory test results are shown in Table 1.

Dr. Westra: Thoracic CT angiography revealed a central filling defect in the distal right pulmonary artery, a finding consistent with pulmonary embolism (Figure 2E). There was also a large right pleural effusion.

Dr. Mauney: A diagnostic test was performed.

Differential Diagnosis

Dr. Stacy A. Kahn: The process of generating a differential diagnosis is iterative. The framework shown below — gather, analyze, review and revise, and create a differential diagnosis — is a simple approach that reminds us that the differential diagnosis often evolves and should be reviewed and revised as we gather new information and analyze the data.

Gather

This patient is a 16-year-old girl with a history of obesity, anxiety, and ADHD who presented with a 5-week history of worsening abdominal pain and diarrhea that progressed to bloody diarrhea. Stool studies were negative, and she had no response to treatment with ciprofloxacin. Three weeks after starting the course of antibiotics, she presented with anorexia, weight loss, nausea, vomiting, fatigue, malaise, headache, mild arthralgias, and myalgias. On examination, she was afebrile and appeared tired, uncomfortable, and pale, with dry mucous membranes. She had lower abdominal tenderness but no rash or jaundice.

Analyze

We can start the diagnostic process by ruling out diagnoses that do not fit with this patient’s clinical picture. Polyps and polyposis syndromes, Meckel’s diverticulum, and vascular malformations can be ruled out because these conditions are not painful or associated with weight loss or systemic symptoms. Intussusception causes abdominal pain but is unlikely in this patient because it is not associated with joint pain, weight loss, or systemic symptoms. Henoch–Schönlein purpura causes abdominal pain and can be associated with joint pain and weight loss, but the hallmark feature is skin involvement, which was not present in this patient. We can also rule out Helicobacter pylori infection and peptic-ulcer disease. These conditions can cause abdominal pain, weight loss, nausea, and vomiting, but without diarrhea or chronic symptoms. In addition, patients with H. pylori infection or peptic-ulcer disease would typically present with reflux symptoms and acute hematemesis or melena. Myalgias and arthralgias are not part of the clinical presentation.

Review

This patient’s initial laboratory evaluation revealed a borderline elevated white-cell count, anemia, hypoalbuminemia, a normal platelet count, mildly elevated aminotransferase levels, and a normal bilirubin level. The C-reactive protein level and erythrocyte sedimentation rate were markedly elevated.

Create a Differential Diagnosis

Patients with inflammatory bowel disease (IBD) — including Crohn’s disease and ulcerative colitis — typically present with bloody diarrhea, abdominal pain, anorexia, weight loss, nausea, vomiting, fatigue, malaise, and arthralgias, with no response to antibiotics. These findings are similar to those observed in this patient. Her borderline elevated white-cell count, elevated erythrocyte sedimentation rate, anemia, and hypoalbuminemia could be consistent with IBD. However, her C-reactive protein level was higher than would be expected with this condition, and she did not have thrombocytosis, which is typical of a flare of IBD. Nevertheless, IBD is still high on the list of possible diagnoses, and further evaluation that includes upper endoscopy and colonoscopy is warranted.

Other chronic conditions, particularly rheumatologic diseases, should be included in the differential diagnosis, given the elevated C-reactive protein level and erythrocyte sedimentation rate, as well as the arthralgias, fatigue, and malaise. The predominance of gastrointestinal symptoms and the absence of arthritis, rash, and fever would be somewhat atypical for a rheumatologic diagnosis. Additional laboratory testing that includes tests for antinuclear antibodies and complement levels will be important.

Although the stool studies were negative, infection should still be considered, particularly zoonotic infection because of the patient’s exposure to animals at school and at home. However, she had no fever, rash, or respiratory or neurologic symptoms.

Like IBD, cancer can be associated with many of the signs and symptoms that were observed in this patient, including anorexia, weight loss, fatigue, and a markedly elevated C-reactive protein level. However, she had no fever, night sweats, or lymphadenopathy.

Revise

After the patient was admitted to the hospital, colonoscopy was performed and revealed findings that were highly suggestive of severe colonic ischemia.1 The differential diagnosis should be revised to include colonic ischemia, a relatively rare diagnosis in children and young adults. Potential causes of colonic ischemia include infections such as coronavirus disease 2019, multisystem inflammatory syndrome in children, tuberculosis, and sepsis. Because the patient had been exposed to agricultural settings, we should consider farm-related toxins, such as insecticides, rodenticides, snake venom, and spider toxins. Drug-induced colonic ischemia is rarely reported in children and is associated with the use of nonsteroidal antiinflammatory drugs, oral contraceptives, antipsychotic medications, illicit drugs, immunosuppressants, and vasoconstrictors, none of which this patient had taken. Cardiovascular disease and end-stage kidney disease can cause colonic ischemia but are not consistent with this patient’s history.

CT imaging was also performed. In addition to findings in the bowel, there was patchy hypoattenuation in the kidneys, which suggests the possibility of ischemia or septic embolism.

On hospital day 5, the patient’s clinical status suddenly worsened, with new tachypnea and tachycardia. The white-cell count increased, and she had worsening anemia, thrombocytopenia, and elevation of the aminotransferase levels. The activated partial-thromboplastin time was prolonged and the d-dimer level was markedly elevated, but the international normalized ratio was relatively normal. Additional imaging studies revealed findings consistent with pulmonary embolism. At this point, several organs — including the lungs, the kidneys, the colon, and possibly the liver — had evidence of thrombotic injury or ischemia. Disseminated intravascular coagulation (DIC) is a consideration, but the relatively normal international normalized ratio is not consistent with this diagnosis. Also, with florid DIC, the severity of illness would be even greater. It is notable that the patient was in a hypercoagulable state in the context of a prolonged activated partial-thromboplastin time. The differential diagnosis should be revised to include hematologic conditions such as bleeding disorders, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis, as well as rheumatologic conditions such as systemic lupus erythematosus, protein C or protein S deficiency, factor V Leiden, systemic juvenile idiopathic arthritis (Still’s disease), vasculitis, and antiphospholipid syndrome (APS).

Overall, this patient had evidence of acute ischemia involving multiple organ systems, without neurologic, dermatologic, or cardiac involvement. She had no evidence of sepsis, infection, or cancer. The family history included autoimmune disease (celiac disease and psoriasis) and first-trimester spontaneous abortion. She was in a hypercoagulable state with thrombosis but did not have DIC. This unusual presentation is so severe and dramatic that it is catastrophic. Taking this all into account, I think that this patient’s diagnosis is catastrophic APS (CAPS).

Dr. Stacy A. Kahn’s Diagnosis

Catastrophic antiphospholipid syndrome.

Diagnostic Testing

Figure 3. Colon-Biopsy Specimens.

Dr. Sarah B. Mueller: Histologic examination of biopsy specimens of the rectum, sigmoid colon, and distal transverse colon revealed normal colonic mucosa with occasional dilated crypts (Figure 3A). A biopsy specimen of the transverse colon from the area adjacent to the mass showed marked mucosal edema, hemorrhage, distorted colonic crypts, and multiple fibrin thrombi (Figure 3B). No classic changes associated with ischemic injury were identified, and immunohistochemical stains for cytomegalovirus and herpes simplex virus types 1 and 2 were negative. Taken together, these findings were not consistent with IBD and were instead suggestive of a thrombotic disorder.

An initial blood specimen was sent to the coagulation laboratory on hospital day 2. The prothrombin time was within the normal range (14.4 seconds), and the activated partial-thromboplastin time was prolonged (53.6 seconds). Testing for factor Xa was negative, which indicated the absence of heparin, low-molecular-weight heparin, heparin analogues, and factor Xa inhibitors. Testing for lupus anticoagulant was positive and did not show correction in a 1:1 mix of the patient’s plasma with normal plasma, which indicated the presence of an inhibitor (e.g., a lupus anticoagulant), rather than a factor deficiency. The confirmatory hexagonal phase phospholipid neutralization assay was positive. Taken together, these results are considered to be positive for a lupus anticoagulant. However, it is important to note that the patient’s C-reactive protein level was highly elevated on admission. C-reactive protein can bind to the phospholipids that are present in the reagents of the lupus anticoagulant assay and the hexagonal phase assay, and the hexagonal phase assay is known to have false positive results when the C-reactive protein level is similar to the level observed in this patient.2-5 Testing for anticardiolipin IgG and IgM, anti–β2-glycoprotein I IgG and IgM, antiprothrombin IgG, antiphosphatidylserine IgG and IgM, and anti–phosphatidylserine–prothrombin IgG and IgM was negative.

A specimen obtained for a full hypercoagulability panel was sent to the coagulation laboratory on hospital day 5. The prothrombin time and activated partial-thromboplastin time were prolonged, and both were corrected in a 1:1 mix. These findings are consistent with factor deficiencies. The levels of factors V, VII, XI, and XII were low; the levels of natural anticoagulants protein C and antithrombin III were low; the level of protein S was low-normal; and the levels of factors II, VIII, IX, and X were normal. These results are suggestive of evolving liver dysfunction. Although the results of liver-function tests were only mildly abnormal on admission, a specimen obtained later in the day on hospital day 5 showed clinically significant elevation in the levels of aspartate aminotransferase and alanine aminotransferase (Table 1). Testing for activated protein C resistance, which is primarily used to screen for factor V Leiden, was normal, as was genetic testing for prothrombin G20210A. Hereditary protein C and antithrombin III deficiencies were ruled out on subsequent testing.

The diagnostic criteria for APS that have been proposed by the International Society on Thrombosis and Haemostasis require laboratory identification of a lupus anticoagulant, anticardiolipin antibody, or anti–β2-glycoprotein I antibody in two blood specimens, with testing performed 12 or more weeks apart and within 5 years after an imaging-confirmed thrombotic event or pregnancy complication.6 Therefore, the diagnosis at this stage in the patient’s course was presumptive, pending confirmation of a lupus anticoagulant or relevant antibody after at least 12 weeks.

Pathological Diagnosis

Antiphospholipid syndrome.

Hospital Course

Dr. Nora AlFakhri (Pediatrics): Treatment with high-dose methylprednisolone, intravenous immune globulin (IVIG), rituximab, and eculizumab was started. On hospital day 9, the aminotransferase levels increased, coagulopathy worsened, and new encephalopathy and lactic acidosis developed; these changes were suggestive of acute liver failure. Additional imaging studies were obtained.Figure 4. Additional Imaging Studies.

Dr. Westra: Doppler ultrasonography of the liver revealed a lack of flow in the main portal vein and its branches, a finding indicative of occlusive portal vein thrombosis (Figure 4A). CT angiography of the abdomen and pelvis confirmed the presence of portal vein thrombosis and revealed additional thrombi in the superior mesenteric vein, splenic vein, inferior mesenteric vein, and inferior vena cava (Figure 4B and 4C). There was extensive ischemic infarction in the periphery of the liver and the left kidney.

Dr. AlFakhri: An infusion of heparin was started. A transjugular intrahepatic portosystemic shunt (TIPS) was placed, and thrombectomy of the portal vein and catheter-assisted thrombolysis of the superior and inferior mesenteric veins were performed. However, on hospital day 10, the encephalopathy worsened, and there was massive lower gastrointestinal bleeding. Red cells were transfused, the heparin infusion was stopped, and protamine was administered. Flexible sigmoidoscopy did not identify a source of bleeding. Additional imaging studies were obtained.

Dr. Westra: CT angiography revealed residual thrombi in the splanchnic venous bed that led to revision of the TIPS and imaging-guided thrombectomy of the superior mesenteric vein and splenic vein (Figure 4D, 4E, and 4F). CT of the head revealed extensive thrombosis in the intracranial venous sinuses and left internal jugular vein, findings that were confirmed by means of magnetic resonance angiography.

Discussion of Management

Dr. Jonathan S. Hausmann: CAPS is thought to result from the binding of antiphospholipid antibodies to cell surfaces, which activates endothelial cells, monocytes, and platelets and leads to inflammation, complement activation, and thrombosis. The formation of thrombi in patients with antiphospholipid antibodies is thought to be a multihit process.7 The presence of antiphospholipid antibodies in the blood is the first event, but the antibodies typically do not cause disease until another event occurs. In a registry of children with CAPS, the most common second event was infection (61%). Cancer (17%), surgery (7%), and lupus flares (4%) were other common triggers for CAPS in children.8 Children are more likely than adults to have primary APS (68% vs. 60%), rather than APS that is secondary to a connective-tissue disease. Children are also more likely than adults to have CAPS as the first manifestation of APS (87% vs. 45%) and to have infection as a trigger for the catastrophic event (61% vs. 27%).8

On the basis of the patient’s history, she may have had several risk factors for the development of CAPS. Her mother was noted to have an early pregnancy loss; recurrent early pregnancy losses are characteristic of obstetrical APS. Some studies show that persons may have a genetic predisposition to APS, especially in the presence of some HLA alleles.7 In addition, the patient’s initial diarrheal illness, which was potentially acquired through animal exposure, may have been the trigger for her thrombotic event. However, she did not appear to have connective-tissue disease associated with her CAPS; testing for antinuclear antibodies was negative, as was testing for anti–double-stranded DNA, anti-Smith, anti–U1-ribonucleoprotein, anti-Ro, and anti-La antibodies.

The management of diseases on the APS spectrum needs to be highly individualized and targeted to the patient’s risk factors, antibody profile, and disease manifestations. Factors that increase the risk of thromboembolism include the presence of lupus, prothrombotic mutations, and traditional cardiovascular risk factors.9 Among the antiphospholipid antibodies, lupus anticoagulant is associated with the highest risk of clotting. However, the presence of a greater number of antiphospholipid antibodies at high titers confers a greater risk of thrombosis.10

Finally, thrombotic disease manifestations are important in guiding therapy. For patients with antiphospholipid antibodies and no history of clotting, anticoagulation for primary thromboprophylaxis is generally not recommended, because the annual incidence of acute thrombosis is low.11 For patients with antiphospholipid antibodies and lupus, the administration of low-dose aspirin may be beneficial, even in the absence of a history of thrombosis.9

For patients with antiphospholipid antibodies and a history of unprovoked thrombosis (e.g., patients with APS), long-term thromboprophylaxis is recommended. The standard of care for these patients is warfarin, which is administered to maintain an international normalized ratio of 2.0 to 3.0. Direct oral anticoagulants do not appear to provide any benefits and incur excess risk.12 Low-dose aspirin may be added in patients with arterial thrombosis.

For patients with more severe presentations — such as this patient, who had CAPS with thrombosis in multiple organs — treatment is more aggressive and involves targeting multiple steps within the CAPS cascade. Treatment for CAPS first addresses any precipitating factors that may have triggered the episode, if they are known (e.g., antibiotics taken for an infection). Additional treatment involves inactivating or eliminating the antibodies (plasma exchange, rituximab, or IVIG), reducing inflammation (glucocorticoids or IVIG), preventing complement activation (heparin or eculizumab), and decreasing thrombosis (heparin).

Although data from randomized trials to guide treatment for CAPS in children are lacking, treatment is generally composed of triple therapy, which includes glucocorticoids, anticoagulation, and plasma exchange or IVIG. In a registry of patients with CAPS, all the children who were treated with triple therapy survived the catastrophic event, whereas 26% of the patients in the overall pediatric cohort died.13 More recently, rituximab (an anti-CD20 monoclonal antibody) and eculizumab (which inhibits complement activation) have been used in children with CAPS, with reports of good efficacy.14

In this patient, once the diagnosis of CAPS was made, treatment with methylprednisolone, IVIG, rituximab, and eculizumab was started. Treatment with anticoagulation appears to have been delayed, perhaps because of concerns about bleeding. A heparin infusion was started after additional thrombi in portal and mesenteric vessels were identified.

Follow-up

Dr. AlFakhri: Serial CT of the head and CT angiography of the chest, abdomen, and pelvis were performed, and there was no evidence of worsening of the thrombosis or infarction. However, on hospital day 26, abdominal pain developed with enteral feeding, and another episode of massive lower gastrointestinal bleeding occurred.

Dr. Westra: CT angiography of the abdomen and pelvis revealed intraperitoneal free air, a finding suggestive of perforation due to colonic ischemia.

Dr. AlFakhri: A subtotal colectomy with creation of a Hartmann’s pouch and end ileostomy was performed because of the colonic perforation. After the surgery, treatment with low-molecular-weight heparin was started as a bridge to warfarin therapy. During the subsequent weeks, enteral feeding was restarted, and no further symptoms of colonic ischemia occurred.

Dr. Mueller: Six weeks after hospital admission, testing for lupus anticoagulant was negative, as was testing for anticardiolipin IgG and IgM and for anti–β2-glycoprotein I IgG and IgM. It is possible that the initial lupus anticoagulant assay had been falsely positive in the context of the elevated C-reactive protein level. Alternatively, the repeat lupus anticoagulant test could have been negative because of the aggressive and early treatment with methylprednisolone, IVIG, rituximab, and eculizumab. The patient continued to receive treatment for CAPS, including methylprednisolone that was transitioned to prednisone. Nine weeks after hospital admission, the patient was discharged to a rehabilitation facility.

Five months after hospital admission, repeat testing for lupus anticoagulant was initially positive but showed correction in a 1:1 mix, a pattern that is expected in the context of factor deficiencies due to warfarin therapy. The confirmatory hexagonal phase assay was negative. Testing for anticardiolipin IgG and IgM and for anti–β2-glycoprotein I IgG and IgM remained negative. Repeat imaging studies showed resolution of the sinus thrombosis and pulmonary embolism, as well as a patent TIPS and splanchnic circulation. The patient continues to receive low-dose prednisone, rituximab, and warfarin. There are plans for ostomy reversal.

Final Diagnosis

Catastrophic antiphospholipid syndrome.

Source: NEJM

Is it time for redefining oligometastatic disease? Analysis of lung metastases CT in ten tumor types


Abstract

Background

Oligometastatic disease (OD) is usually defined arbitrarily as a condition in which there are ≤ 5 metastases. Given limited disease, it is expected that patients with OD should have better prognosis compared to other metastatic patients and that they can potentially benefit from metastasis-directed therapy (MDT). In this study, we attempted to redefine OD based upon objective evidence that fulfill these assumptions.

Discussion

The concept of OD envisioned by Samuel Hellman in 1995 has attracted much attention in recent years [1,2,3,4,5, 8, 11, 12]. It hypothesizes an interim condition in which a tumor has spread to only a few sites and cure by MDT may be possible. Unfortunately, there is no reliable biomarker for OD and no universally accepted definition [10]. In most studies, OD was arbitrarily defined as a condition in which there are five metastases or less in imaging studies that are technically treatable with MDT [7]. In this study, we suggest adding metastases clonal origin to the definition of OD to identify those patients with greatest chance for cure by MDT.

Tracking a given metastasis’ clonal origin is not an easy task. It requires retrieval of tumorous tissue and complex genetic and epigenetic studies [13,14,15]. However, in a previous study it was showed that the relatively straightforward analysis of metastases number and diameter may provide readily available information regarding clonal origin by differentiating between linear and parallel patterns of appearance [9]. In brief, the linear model asserts that when a malignant clone gains the capabilities needed to become a metastasis (invasion, angiogenesis etc.); a cluster of metastases disperses from this clone. Since all these metastases have the same clonal origin and commission time, a similar growth rate is expected at any landing site. Thus, all metastases originating in that clone have a similar diameter in any specific organ at any time point. Additional clones may reach this maturity and spread as clusters of metastases but for each cluster, a distinct diameter of all its metastases is expected. By contrast, the parallel model suggests early spread of disseminated tumor cells (DTCs). These cells mature to metastases independently in the target organs and are therefore expected to be at varying diameters. LPR quantitatively displays how much of the tumorous spread was linear and how much parallel. LPR =  + 1 means unmixed linear spread and LPR = − 1 unmixed parallel.

Clearly, the ideal patient to be defined as possessing OD will have a pure a linear (LPR =  + 1), monoclonal, single cluster of metastases, preferably with only a few tumors technically permitting MDT. Patients with a linear multi-clonal or parallel metastatic spread have a more genetically diverse disease and are expected to respond less well to MDT. It is therefore anticipated that a patient with “true” OD will demonstrate a better prognosis compared to patients with non-OD.

In this study using chest CTs of patients with lung metastases originating in ten different malignancies, we showed that patients with a single metastasis or a single cluster of metastases demonstrating diameter variations of 1 mm or less can be classified together into a group possessing significantly better prognosis compared to other patients with metastatic disease (Table 1 and Figs. 1a and 2a). We also showed that if metastases diameter is ignored, the prognosis of patients with 2–5 metastases is similar to that of patients with 6–10 metastases; supporting the concept the five metastases upper limit requirement of OD is probably not biologically true. (Fig. 1b).

Not all tumor types showed the same prognostic dependence on the number of metastases and metastatic clusters. Metastases number had no significant prognostic impact in cancers of the breast, prostate, thyroid, pancreas, and stomach. This is probably due to the small number of patients with a single metastasis in these tumors (only 2, 1, 0, 7, and 3 patients with these tumor types respectively). Metastatic cluster number had no significant impact on the prognosis of patients with tumors of the bladder, breast, melanoma, prostate, and stomach. This could also stem from a small number of patients with a single metastases cluster (only 3, 6, 4, 10, and 8 patients with these tumor types respectively).

Variability of metastases number between clusters and LPR also showed a highly significant impact on OS (p < 0.0001). Both parameters are related to genetic diversity of the metastases. This observation is important scientifically and supports the previous conclusion. However, since these parameters are less intuitive and require computerized calculation, it is suggested not to include them in the definition of the OD. As stated earlier, a single cluster means LPR =  + 1. In search of confounders to this model, the features of patients with single and multiple clusters of metastases were compared (supplementary material S5). Tumor’s origin and patients’ age were similar but there were significantly more men than women in the single cluster group (66.4% Vs. 52.9%, p = 0.06). Gender itself had no significant effect on OS (supplementary material S6) so the significance of this finding is not clear and merits further studies.

The model presented here, with the suggestion of qualifying only patients with a single metastatic cluster (representing a single clone) in the definition of OD, is obviously oversimplified. Yet it could be useful for planning clinical research in OD and may potentially provide better results compared to the poor results obtained with the standard definition of five metastases or less [3,4,5, 8].

We acknowledge that this study has several notable limitations:

  1. 1. Although patients with a single cluster of metastases showed significantly better prognosis, this may not automatically translate into better response to MDT.
  2. 2. Metastases growth rate may be influenced by proximity to anatomical structures; thus, metastases originating in a single clone may grow at different rates and mimic several clones.
  3. 3. Similarly, an earlier slow growing clone can reach the same diameter as a later but faster growing clone. In this way, several clones may mimic a single clone. Given the improved survival of patients with a single cluster noted according to the proposed model, this condition is unlikely.
  4. 4. This study was performed on lung metastases only. Measurement of metastases diameter in other organs is less straightforward and may show different results. Thus, further assessment of these alternative tumor microenvironments will be necessary.
  5. 5. Primary tumor control and metastases outside the lungs were not considered in the analysis. As shown by Niibe et al. patients with 1–5 metastases after control of the primary tumor (oligo-recurrent disease) have good prognosis with three-year OS of 64% after SABR [12].
  6. 6. Only metastases largest diameter was considered here, due to the simplicity of its measurement. Future studies assessing the potential role of lesion volume and perhaps using deep learning techniques are encouraged.

In summary, this study addresses OD from a biologic/pathophysiologic rather than surgical/anatomic point of view. We demonstrate that patients with a single cluster of metastases, potentially originating from a single clone, even with more than five lesions, have significantly better prognosis compared to patients with polyclonal disease. Accordingly, we propose including monoclonality in the definition of OD. The upper limit of metastases number should not be set arbitrarily and should be determined by the technical capabilities of the MDT. These criteria can potentially improve patient selection for MDT and provide a higher percentage of curative procedures for patients with metastatic disease.

Fig. 3

Representative scans of patients diagnosed with a few metastases with similar diameters representing a single (presumably monoclonal spread) cluster. a-liposarcoma, b-pancreas, c-stomach. These patients are suitable for inclusion in an oligometastasis trial. Patients were diagnosed with few metastases but with different diameters (presumably representing multiclonal spread) d-colorectum, e-melanoma, f-osteosarcoma. Despite having only a few metastases, these patients may not be suitable for inclusion in an oligometastasis trial,

Source: springer.com

The Unexpected Connection Between Stress and Bloating


(AstroStar/Shutterstock)

)

We all know the feeling of an expanded stomach after a particularly indulgent meal. But beyond the occasional bloating experience, nearly a third of the U.S. population experiences chronic bloating [1]. So what’s behind this symptom when it’s more frequent?

Key Takeaways

  • Stress can lead to bloating by increasing inflammation and causing gut bacteria imbalances.
  • Irritable bowel syndrome (IBS) symptoms, including bloating and abdominal distention, are strongly associated with stress levels.
  • Non-gut-related issues, like pelvic floor dysfunction, can cause chronic bloating.
  • Bloating and other gastrointestinal (GI) symptoms can be easily treated with lifestyle and dietary changes, probiotics, and physical therapy.

If you’ve been going through a lot more stress than usual lately, you may have noticed a worsening in your symptoms. And you wouldn’t be wrong, as the research shows that increased stress can worsen bloating and stomach distention.

The link between stress and increased IBS symptoms like bloating is well-established. This is likely due to stress changing the gut microbiota, leading to dysbiosis and/or bacterial overgrowth. These gut flora changes can lead to excess gas production and inflammation inside the GI tract. Unfortunately, as inflammation levels increase, our pain sensitivity also increases, adding to the sensation of bloating.

Fortunately, dietary, lifestyle, and supplemental recommendations are effective at reducing the underlying causes of stomach bloating. This article will take you through some of the most common causes of bloating that result from stress, and will give you a step-by-step guide to alleviating this uncomfortable symptom.

Can Stress Cause Bloating?

Stress can disrupt the normal gut microbiome, creating intestinal dysbiosis and bacterial overgrowth. These changes can lead to digestive symptoms, including bloating. This may be due in part to excess gas production that may cause the sensation of bloating and physical distention, though the exact mechanism hasn’t been confirmed by research.

Additionally, it appears that stress creates an increased perception of bloating, though the exact reason is not well understood [2]. Stress likely causes inflammation in the digestive tract that increases pain receptors, creating more distress related to bloating.

What Is Bloating?

Bloating is the subjective feeling of pressure or gas in the abdomen. It’s important to note that this is different from distention, which refers to the physical expansion of the abdomen [1]. However, these symptoms often present together, and over half of the people who experience bloating also report abdominal distention [1].

Bloating may exist as a symptom on its own, without other signs of GI disturbance. However, it often presents alongside other GI disorders, such as:

  • Irritable bowel syndrome (IBS) [1]
  • Inflammatory bowel disease (IBD) [3]
  • Small intestine bacterial overgrowth (SIBO) [1245]
  • Chronic constipation [1]
  • Dyspepsia and indigestion [1]
  • Exocrine pancreatic insufficiency (EPI) [1267]
  • Gastroparesis [12]
  • Gallbladder dysfunction [8]
  • Stomach ulcers [9]
  • Chronic overeating [5]

Occasional bloating, flatulence, belching, and distention are all considered normal parts of digestive physiology, especially after eating. These symptoms typically aren’t considered a problem until they begin to cause pain and/or disrupt your daily life.

Let’s take a look at some cases where this can occur.

Stress and Irritable Bowel Syndrome (IBS)

IBS is a common gut disorder and is a frequent cause of bloating and abdominal distention. One study found that all patients with diagnosed IBS, regardless of the subtype, experience more sensations of bloating than healthy controls. Furthermore, nearly half of IBS patients experienced physical abdominal distention [10].

The link between stress and IBS is well-researched, and chronic stress often increases IBS-related symptoms such as:

  • Gas, bloating, and abdominal distention
  • Constipation
  • Diarrhea
  • Stomach pain
  • Cramping

Those with IBS tend to struggle with mental health disorders, and research shows that they experience higher levels of depression, anxiety, and distress than the general population [11]. Additionally, people with IBS tend to have higher levels of stress and a lower quality of life [12].Fortunately, IBS can be treated with functional medicine, offering some much-needed relief for IBS-related mood disturbances.

While we’re unsure of the exact mechanism by which stress increases symptoms of IBS, studies show that stressors alter the microbial balance and production of gut flora metabolites. This change in the microbiome then causes physiological changes in the brain via the gut-brain axis [13].

When the brain creates a stress response, chemical messengers—like stress hormones and neurotransmitters—travel down the gut-brain axis and can cause hypersensitivity in the gut. In fact, research shows that IBS patients may not actually experience more gas production than healthy populations. It’s likely a hypersensitivity reaction in the enteric nervous system that leads to increased sensations of bloating [14].

Regardless of the exact mechanism, there appears to be a strong correlation between IBS symptoms and stress.

Epoch Times Photo

Bloating in Other GI Conditions

Because of the communication between the digestive system and the brain, stress likely increases symptoms of bloating and abdominal distention in other functional GI disorders.

For example, as stress can cause dysbiosis in the digestive tract, it’s likely a major contributing factor in the development of small intestinal bacterial overgrowth (SIBO). Additionally, exocrine pancreatic insufficiency and histamine intolerance both frequently present with bloating, and are likely aggravated by chronic stress [1516].

Food intolerances and allergies commonly present with bloating and are another example of how stress affects the GI tract [1718]. For example, sensitivities like wheat and gluten intolerance are caused by a misguided immune reaction in the gut. As stress creates inflammation and an abnormal immune response in the digestive tract, it may also lead to the development and persistence of these sensitivities.

Other Possible Causes of Bloating

Many other chronic health conditions can often present with abdominal bloating and distention. This includes disorders and other underlying factors like:

  • Certain medications
  • Hypothyroidism [12]
  • Obesity [1]
  • Type-2 diabetes [2]
  • Autoimmunity [21920]
  • Menstruation and ovarian cysts [212223]

Even musculoskeletal disorders are often triggered by stress and can cause increased bloating and abdominal distention. The following are two examples of when this may occur.

Abdominal Muscle Dysfunction

Abnormal contractions in the diaphragm and belly muscles after eating can cause the nervous system to create a heightened sense of bloating. This abnormal “viscerosomatic reflex” causes poor posture and distention of the abdominal muscles, and may worsen bloating sensations [24].

Exercises that retrain the muscles to contract in a normal way after eating may reduce the perception of bloating [24].

Pelvic Floor Dysfunction

Stressful situations naturally cause our muscles to tighten and can lead to increased contractions in the muscles of the pelvic floor. These muscles control our bladder, bowel, and sexual function. When they are overly contracted (too tight) they can create a condition known as high-tone pelvic floor dysfunction [25].

Conversely, the opposite can happen when the pelvic floor muscles become overly relaxed, making it difficult to have regular bowel movements. In either case, both increased tone and over-relaxation of these muscles can lead to a wide array of symptoms, including bloating [25].

It’s believed that people with pelvic floor dysfunction likely have disordered gut-brain connections [26]. Biofeedback is a mind-body therapy that teaches your body how to relax and can help restore the gut-brain axis. One clinical trial on women with pelvic floor dysfunction found that over half of the participants had decreased bloating after undergoing biofeedback [26].

This positive response further strengthens the evidence that our brains and digestive tracts are connected. Overall, stress appears to increase the likelihood of bloating by affecting multiple body systems, including the digestive, nervous, and musculoskeletal systems.

woman speed walking through a park
As little as 20 minutes of fast walking can be enough to lower inflammatory markers in the body. (michaelheim/Shutterstock)

Your 5-Step Guide to Reducing Stress-Induced Bloating

While much of the following research on relieving stress and GI symptoms was performed on those with IBS, we’ve found the below therapies to be helpful for people with other conditions that result in bloating and abdominal distention.

Step 1: Lifestyle Changes

Stress management: Stress-reduction techniques can reduce the “fight or flight response” that happens during times of stress and can improve your gut health. Cognitive behavioral therapy (CBT), biofeedback, and meditation all help reduce stress levels and relieve stress-induced bloating [272829].

One meditation technique in particular, mindfulness-based stress reduction (MBSR), shows promise in reducing bloating and overall stress levels. Additionally, results may last up to six months after undergoing MBSR therapy [303132].

Gut-directed hypnotherapy may also significantly reduce symptoms of bloating, anxiety, and depression. These effects were seen in as few as six sessions [333435].

Exercise: Physical activity is beneficial for improving stress, alleviating uncomfortable GI symptoms, and improving overall wellness. For the best results, aim to engage in moderate physical activity for two to three hours per week [36]. This includes activities like:

  • Fast walking
  • Biking on a flat surface
  • Water aerobics
  • Basketball, tennis, volleyball, and other sports

Yoga also appears to be an effective exercise for reducing bloating and is well-known to help reduce stress and anxiety levels [37].

Step 2: Change Your Diet

Start by following an elimination diet to help heal your gut, reduce inflammation, and determine which foods might be triggering your symptoms.

A good place to start is with a Paleo diet framework. The Paleo diet emphasizes high-protein, high-fat, and low-carbohydrate consumption. It reduces inflammation in the intestinal tract and can be effective at eliminating digestive symptoms, like bloating and distention. This is a well-rounded diet that eliminates several common triggers without being overly restrictive.

Common triggers that are eliminated on the Paleo diet include:

  • Sugar
  • Processed foods
  • Gluten-containing foods and other grains
  • Dairy

If, after trying it for two to three weeks, the Paleo diet doesn’t work for you, try switching to a low FODMAP diet. Clinical trials show that a low FODMAP diet is highly effective at reducing abdominal pain, gas, and bloating, while improving the overall quality of life [3839404142].

Try the low FODMAP diet for two to three weeks and see if your symptoms improve. If they do, it may not be necessary to continue to follow a strict low FODMAP protocol to maintain relief from your symptoms, as 84 percent of participants in one study still experienced relief from their digestive symptoms, even after reintroducing a few FODMAP foods [43]. In fact, long-term restriction of FODMAP foods may actually worsen symptoms, as it suppresses the growth of healthy gut flora [44].

It is important to note that everyone’s food triggers may be different and it may take some experimentation to figure out what may be causing your bloating and other GI symptoms.

Once you eliminate all of the suspected triggers from your diet, you can start adding foods back in, one at a time. Introduce a new food every two to three days, and watch to see if you experience any bloating or distention. This will allow you to identify your unique gut triggers, without being overly restrictive.

Step 3: Introduce Probiotics

Probiotics are highly effective at reducing symptoms of GI disorders, including bloating and abdominal distention [45464748]. Probiotics help to dampen the dysbiosis that occurs from stress and can help restore the normal gut flora.

In patients with IBS, probiotics can significantly reduce abdominal pain, and even help to alleviate bloating and diarrhea that accompany menstruation [48495051].

It’s important to note that prebiotics, food-based supplements that promote the growth of beneficial gut bacteria, may not offer the same benefits [52].

dietary supplements
Dietary supplements. (Wikimedia Commons)

Step 4: Targeted Supplement and Dietary Treatments

If your bloating and/or stomach distention isn’t solved by dietary and lifestyle changes alone, it may be time for a more targeted approach.

  • Supplements: Research suggests that digestive enzymes can help reduce symptoms of bloating, abdominal pain, and flatulence [5354]. One enzyme in particular, ɑ-galactosidase, may be beneficial in alleviating colic in children and is considered to be safe [55].
  • Intermittent Fasting: One study showed that intermittent fasting successfully reduced bloating, abdominal pain, diarrhea, nausea, and anxiety in those with IBS [56]. Intermittent fasting focuses on abstaining from eating for a certain period each day. Many people start with a 16-hour fasting window, but there are many variations, and you should always do what’s best for you.
  • Elemental Diet: Don’t worry if fasting isn’t appropriate for you, as an elemental diet can effectively resolve stubborn IBS-related symptoms, like gas and bloating, in just two to three weeks [57]. The elemental diet is formulated to be easily digested, it reduces inflammation in the GI tract, and helps increase nutrient absorption. The elemental diet is easy to incorporate and can be used alone, or alongside another diet.
  • Medications: Rifaxamin is a popular antibiotic that’s used to treat dysbiosis and infections in the GI tract. It’s considered safe by health care practitioners, as it’s not absorbed into the bloodstream, lessening its side effects. Rifaxamin is highly effective at reducing IBS symptoms, particularly bloating, and it may take as little as two weeks to see significant results [58]. Furthermore, rifaxamin may offer long-term relief from bloating, even after finishing the course of antibiotics [59].

Step 5: Physical Therapy

Those with bloating related to pelvic floor dysfunction may benefit from seeing a physical therapist who specializes in pelvic floor therapy. Manual physical therapy can effectively break up adhesions (scar tissue) that constrict organs and lead to abdominal distension and bloating sensations [60].

As previously discussed, pelvic floor biofeedback may help alleviate bloating, lessen constipation, and improve overall well-being [26].

Epoch Times Photo

Summary: Can Stress Cause Bloating?

Research supports that stress is a likely cause of bloating in both GI disorders and non-gut-related conditions. The gut-brain axis provides a powerful pathway of communication between the brain and digestive tract, allowing stress to increase inflammation and dysbiosis in the gut.

Fortunately, there are some basic steps that you can take to improve your symptoms of bloating and abdominal distention.

Stress reduction, dietary changes, probiotics, supplements, and even physical therapy are all likely effective in improving bloating.

Should alcohol carry a warning label?


There is no safe level of alcohol consumption, according to updated guidelines from the Canadian Centre on Substance Use and Addiction (CCSA).

The guidelines recommend consuming no more than two alcoholic drinks per week. That’s the equivalent of two bottles of beer, two glasses of wine, or two shots of spirits.

CCSA is also calling on Health Canada, which funded the guidelines, to require warning labels on all alcoholic beverages.

Changing consensus

“All levels of alcohol consumption are associated with some risk, so drinking less is better for everyone,” the guidelines state.

Previously, CCSA suggested a maximum of 10 drinks per week for women and 15 per week for men — recommendations that form the basis of Health Canada’s alcohol guidelines.

But the scientific consensus on the health impacts of alcohol has changed in the past decade, with studies showing that even small quantities can be harmful.

According to CCSA’s review of more than 5000 studies, three to six standard drinks per week pose a moderate health risk, including an increased risk of cancer, while seven or more drinks pose increasingly higher risks, including for heart disease and stroke.

The lifetime risks associated with more than two drinks per week also increase more steeply for women than men due to a host of biological differences.

Low awareness of alcohol risks

Many people in Canada are unaware of these risks, according to CCSA. More than half of people over age 15 consume more than two drinks per week. Two in five are not aware alcohol is carcinogenic. And the notion that drinking in moderation protects the heart is still widely publicized, despite systematic reviews debunking the claim.

CCSA and the Canadian Cancer Society argue the federal government should require warning labels on alcohol packaging to inform people about the cancer risk and how many standard drinks are in every container.

Consumers “have a right to clear and accessible information about the health and safety of the products they buy,” according to CCSA.

International debate

The guidelines have sparked debate internationally, with BBC News dubbing the guidelines as “drastic” compared to recommendations in other countries.

Australian and French guidance recommend a maximum of 10 drinks per week, while the United Kingdom suggests no more than 14 units or six standard drinks.

However, according to the World Health Organization, half of all alcohol-attributable cancers in Europe are caused by such “light” and “moderate” consumption.

“We cannot talk about a so-called safe level of alcohol use,” said Carina Ferreira-Borges, regional advisor for alcohol and illicit drugs in WHO’s European office. “The only thing that we can say for sure is that the more you drink, the more harmful it is.”

The WHO has echoed the call for warning labels noting that alcohol has long been categorized as one of the highest-risk carcinogens alongside tobacco, asbestos and radiation.

Do alcohol warning labels work?

In one of the only real-world experiments of cancer warnings on alcoholic beverages, labels on products in Yukon liquor stores were found to decrease per capita alcohol sales by more than 6% compared to control sites.

“What we learned from that study was that the cancer labels grabbed consumer attention,” study coauthor Erin Hobin told CBC News. “They read the cancer warning very closely. They thought about that message. They talked to their neighbours and friends about that message.”

However, the study was cut short, likely owing to alcohol industry pressure.

Industry representatives have also questioned CCSA’s methodology and called for an independent review of the updated guidelines.

According to CJ Hélie of Beer Canada, the alcohol industry already voluntarily informs people to drink responsibly, so there’s no need for any labels.

For example, Wine Growers of Canada is developing a QR code that manufacturers could use voluntarily to direct consumers to information about responsible drinking.

Duty to inform

Some experts argue that such initiatives don’t go far enough to fulfill the industry’s legal duty to inform consumers clearly about health risks, especially if those risks are not well known.

Health warnings “are not just critical, they are required under the law,” and a manufacturer’s obligation to inform is greater when a product is ingested, according to Jacob Shelley, co-director of the health ethics, law and policy lab at Western University.

In the case of tobacco, warning labels have been effective in attracting consumers’ attention and increasing health knowledge, but their impact on behaviour can wear off over time and varies depending on the size and design of the warning.

Health Canada appears reluctant to weigh in on the issue. Although the agency acknowledged to the media that alcohol presents serious and complex public health and safety issues, it has declined to comment on requiring warning labels.

Pneumopericardium as a complication of pericardiocentesis


A 48-year-old man with trisomy 21 was transferred to our cardiology service because of acute dyspnea. At presentation, his blood pressure was 70/50 mm Hg, with a heart rate of 130 beats/min and an oxygen saturation of 88%. Physical examination showed muffled heart sounds, clear lungs and distention of the jugular veins. An echocardiogram showed a large circumferential pericardial effusion.

We performed fluoroscopy-guided pericardiocentesis, under local anesthesia, through the subxiphoid approach and inserted a pigtail catheter (8Fr). Drainage of 1000 mL of transudate resulted in rapid clinical improvement. A chest radiograph at 24 hours showed air entrapment between the cardiac silhouette and the pericardium, without signs of pneumothorax (Figure 1). A repeat echocardiogram showed bright echogenic spots swirling in the pericardial cavity, impairing visualization of cardiac structures (video Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.221137/tab-related-content). We made the diagnosis of pneumopericardium. Because he was hemodynamically stable, we treated him conservatively and the pericardial air gradually resolved. Diagnostic work-up to identify a cause of his pleural effusion was negative; therefore, we considered the pericardial effusion to be idiopathic.

Figure 1:

Chest radiograph of a 48-year-old man after pericardiocentesis, showing air entrapment (asterisk) between the cardiac silhouette and the thin, radiolucent line of the pericardium (arrows).

Pneumopericardium after pericardiocentesis is an uncommon complication that results from air insertion through the pericardial drainage or formation of a direct pleuropericardial communication. The diagnosis is made by chest radiography, computed tomography or echocardiography.1 Differential diagnosis includes pneumomediastinum, in which air does not typically surround the bottom of the heart and is not confined solely to the heart, but can extend to the superior mediastinum and neck.2 In our case, pneumopericardium was likely induced by coughing in combination with an unsealed system. Avoidance of vigorous inhalation or coughing, confirmation of proper drain position (i.e., no side holes outside the pericardial space), closure of all drainage system connections and application of surgical gel to the skin around the drain to create an airtight seal are essential to prevent this complication.3 Pneumopericardium is usually self-limiting and requires no specific therapy. However, the development of cardiac tamponade necessitates repeat pericardiocentesis or surgical decompression.

Want to Burn Belly Fat? Try This Kind of Food


(Shutterstock)

Losing weight is not easy, and losing belly fat is even harder. Is there a simple and effective way to lose that stubborn fat? The answer is yes. Just adding a certain amount of soluble fiber to your food can help melt belly fat away.

Two Kinds of Plant Fibers

There are two types of plant cellulose: Soluble and insoluble. Insoluble means it is not able to be broken down by the water and is excreted directly by the body. Eating an excess of insoluble cellulose can cause diarrhea.

Water-soluble cellulose plays an important role in our digestive tract and has a lot to do with our health and weight.

The Role of Soluble Plant Fiber

The first role of soluble plant fiber is to help the body lose excess weight by absorbing water in our digestive tract and then expanding it. As a result, we experience a feeling of satiety and reduce the tendency to overeat. If you do happen to eat too much soluble plant fiber, you may become constipated due to the absorptive factor in the intestines.

The second role of soluble plant fiber is its ability to nourish the microbiota of the gastrointestinal tract. Our body’s microbiome resides in our nasal, oral, respiratory, reproductive, and digestive tracts and is most abundant in the digestive tract. These microorganisms include protozoa, fungi, viruses, and bacteria. Among them, bacteria account for the majority. There are at least 100 trillion bacteria within the human body.

Soluble plant fiber can feed the microbiome in our body. The health of the microbiome is essential to us. They protect the integrity of the lining of our gastrointestinal tract and help the lining of the gastrointestinal tract to perform its functions. It can also help us metabolize food so that the nutrients in food can be fully absorbed and utilized. On top of that, the microbiota also reduces inflammation in our gastrointestinal tract.

Studies have found that the level of gastrointestinal microbiota is inseparable from our digestive, immune, and nervous system functions. Many autoimmune and neuropsychiatric diseases are related to an imbalance of the intestinal flora.

Another benefit of soluble fiber is to enhance blood sugar balance. Although it is a carbohydrate, soluble fiber does not generate calories and can adjust the body’s sensitivity to insulin and blood sugar balance.

Foods Containing Soluble Fiber

Not all soluble cellulose has this effect—only thick and sticky cellulose exhibits this function. Because this kind of cellulose can stay in the gastrointestinal tract for a long time and makes us feel full, it brings about various biochemical effects.

Which foods contain this viscous soluble cellulose? All kinds of beans, flaxseed, asparagus, Brussels sprouts, and oats.

Worth noting is that the effects of fiber supplements are not as good as fiber derived from whole foods—and eating food containing 30 grams (1 oz) of fiber per day, is effective.

To summarize, in conjunction with a healthy lifestyle, a daily intake of at least 30 grams (1 oz) of soluble viscous cellulose aids in weight loss. Soluble fiber comes mainly from beans, green vegetables, and oats. Remember—don’t eat too much soluble fiber at once as it can cause constipation.